According to @mcuban, many cell and gene therapies are being carved out of payer plans, their prices are not falling, and some companies behind these therapies are getting acquired, underscoring persistent pricing power and consolidation pressure in CGT equities, source: https://twitter.com/mcuban/status/1995215355401171252. He adds that stakeholders are evaluating new payment models and points to a federal initiative, the CMS Cell and Gene Therapy Access Model, as a key framework under consideration, source: https://twitter.com/mcuban/status/1995215355401171252. CMS describes its CGT Access Model as enabling multi-state value-based purchasing and outcomes-based agreements to improve Medicaid access for high-cost cell and gene therapies, indicating payment structures that can tie reimbursement to patient outcomes, source: https://innovation.cms.gov/innovation-models/cgt-access-model. CMS further notes the model can centralize negotiation and administration of outcomes-based agreements on behalf of states, including outcome measures and financial terms such as rebates if outcomes are not achieved, which directly affects reimbursement mechanics and revenue recognition for CGT manufacturers, source: https://innovation.cms.gov/innovation-models/cgt-access-model.

According to Mark Cuban, there is an important opportunity for those taking a specific medication to access it at a reduced cost, even for those with insurance. This could potentially affect pharmaceutical investments and market strategies for investors considering the impact on drug pricing and access channels.

According to Mark Cuban's tweet, his support for CostPlus Drugs could influence healthcare stock traders by highlighting the potential market disruption caused by lower drug pricing, which may impact pharmaceutical company valuations.